RecruitingPhase 2NCT06807580

Progesterone in Gender Affirming Hormone Therapy Study

Effects of Oral Progesterone in Transgender Women on Breast Development, Sleep Quality, Psychological Distress, and Cardiovascular Risk

Sponsor

Emory University

Enrollment

40 participants

Start Date

May 12, 2025

Study Type

INTERVENTIONAL

Conditions

Transgender Women

Summary

This study aims to study the effects of Oral Progesterone in Transgender Women. The primary goal is to study the effect of progesterone on psychological distress and secondarily on sleep quality, breast size, quality of life and gender congruence and cardiovascular risk.

Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called Progesterone for people with transgender women. The study is currently recruiting participants at 1 location. People eligible for this study include men aged 18 Years to 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPlacebo

The placebo will be nearly identical in size, color, and shape to micronized progesterone

DRUGProgesterone

Oral micronized progesterone 200 mg

Locations(1)

Emory Transgender Clinic

Atlanta, Georgia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06807580

Related Trials

Economic Navigation and Strengthening to Research Unrestricted Services for Transgender Women (ENTRUST)

NCT062028981 location